AFJK
Aimei Health Technology Co., Ltd Ordinary Share
NASDAQ: AFJK · FINANCIAL SERVICES · SHELL COMPANIES
$45.96
-0.33% today
Updated 2026-04-29
Market cap
$281.38M
P/E ratio
229.82
P/S ratio
—
EPS (TTM)
$0.20
Dividend yield
—
52W range
$7 – $130
Volume
0.0M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.0
Quality
C+3.5
Profitability
D4.0
Valuation
C—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
$1.36
-97.04%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-96109.00
- P/E 229.82x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Revenue | — | $0.00 | $0.00 |
| Net income | $171389.00 | $2.55M | $352019.00 |
| EPS | — | — | $0.20 |
| Free cash flow | — | $-672289.00 | $-96109.00 |
| Profit margin | — | — | — |
Peer comparison
Smart narrative
Aimei Health Technology Co., Ltd Ordinary Share trades at $45.96. representing a P/E of 229.82x trailing earnings. Our Smart Value Score of 16/100 indicates the stock is weak.
Frequently asked questions
What is Aimei Health Technology Co., Ltd Ordinary Share's stock price?
Aimei Health Technology Co., Ltd Ordinary Share (AFJK) trades at $45.96.
Is Aimei Health Technology Co., Ltd Ordinary Share overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell).
What is the price target of Aimei Health Technology Co., Ltd Ordinary Share (AFJK)?
The analyst target price is $—, representing NaN% downside from the current price of $45.96.
Company info
SectorFINANCIAL SERVICES
IndustrySHELL COMPANIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE—
Beta-1.50
50D MA$34.69
200D MA$26.77
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week+52.45%
1 month+57.75%
3 months-32.98%
YTD-36.88%
1 year—
3 years—
5 years—